Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
about
Recurrent Glioblastoma: Where we standA new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastomaFotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experienceGEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeThe future of high-grade glioma: Where we are and where are we going.Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor GroupEffective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literatureA retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Standards of care for treatment of recurrent glioblastoma--are we there yet?Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experienceBevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.State of the art and perspectives in the treatment of glioblastoma.Nitrosoureas in the Management of Malignant Gliomas.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Patient outcomes following second surgery for recurrent glioblastoma.Bevacizumab in recurrent glioblastoma: open issues.Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.Bevacizumab in brain tumors: ready for primetime?Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?Treatment of glioblastoma in adults
P2860
Q26765042-0B8C1BC1-53C4-4CD1-A9ED-B9CE165CA58EQ33391296-77B848B4-DACF-4CC8-A4E3-1AD68DE5AD1DQ33402044-B65803E2-1082-4DEB-820E-6E5FE666F7B1Q33406919-AB057700-90F0-4D82-B208-B5B2BDFFFCE9Q33411366-CD93D65C-E18A-49D7-9C7F-B3BF01B41D61Q33415187-58964931-23EE-4741-B69C-183B4D63951BQ33427367-547E2870-F7C8-46F1-944B-EEE5DD7F2CDAQ33625227-C99FB338-EA47-460A-89A9-60479D7BB34DQ35027024-BC92B2A1-B772-45F7-92D4-0620AF268E49Q35114090-9DE3036F-79D5-4C0A-973A-B48B7E8AC759Q35188488-A6D36676-6189-4B9B-91EB-F0CF310592F3Q35580650-201DDA04-412E-4361-B5A5-56D738BC66DCQ36143344-227479B3-F6A9-45F8-A43C-29C99C72C0ECQ36367414-C0AD23F0-3F7F-4BE3-A1FF-41645628CB81Q36500401-EC04397A-1D60-47CB-8DFC-B898B5CF5E80Q36935024-F27046C7-175B-4078-8AAF-E2DFAB01DC6FQ37526275-84F1D2CB-F133-4106-A8FD-C2F788C77715Q37952239-F5CD704C-194C-4E46-AC6D-D986572B44E1Q38205133-51A1D54E-C6B2-4471-A015-03D2EF14BD1EQ38209678-34D01707-7B00-4EBB-9CC9-DDC8064E4059Q38233067-9E6CF8AD-B00B-434E-81BD-AE39B6984011Q38691732-AC86984D-F656-4E5A-A25B-3AE6BCB1A4E7Q38720644-AB736BFF-F2D5-484D-BAE6-800490514CDDQ38907846-B100125E-4F70-4432-9476-EA9B38778621Q38965301-D94C09A6-47E4-4434-A408-43CF94B224D0Q39173162-FB9938B3-A792-44C4-A5BA-2D4FB77F4DEEQ41139015-B3AA47DA-9906-4D55-AA3B-CF71E061405BQ42060733-4BF03FC0-7DEB-4648-A162-6E3CC61C9045Q43246067-59729987-699D-4ED3-B990-9A8B41B40789Q45249503-BB29DCFC-CB07-4F4E-9275-20538B69C0D1Q48213840-02075B2E-E694-4446-B5BB-1AED8D770A87Q48425942-DEF34053-799F-4B3D-84DD-82FC1E432FD1Q55463103-B04F8728-089A-4F4A-90B3-905D660EEFD8Q57174802-FBCCC331-6CFE-4B8B-B251-A79E84398ABC
P2860
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@ast
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@en
type
label
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@ast
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@en
prefLabel
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@ast
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@en
P2093
P2860
P1476
Fotemustine as second-line tre ...... vo di Neuro-Oncologia (GICNO).
@en
P2093
C Bianchini
E Franceschi
M Gardiman
P2860
P2888
P304
P356
10.1007/S00280-009-0926-8
P577
2009-01-24T00:00:00Z
P5875
P6179
1046910034